Protease-Sensitive Inhibitory Activity of Cell-free Supernatant of Lactobacillus crispatus 156 Synergizes with Ciprofloxacin, Moxifloxacin and Streptomycin Against Pseudomonas aeruginosa: An In Vitro Study

Probiotics and Antimicrobial Proteins

Volumn 7, Issue 2, 2015, Pages 172-180

  Kaur, Sukhraj ^a   Sharma, Preeti ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

Fluoroquinolones; Lactobacillus crispatus; Probiotic; Pseudomonas aeruginosa; Synergistic activity

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL DNA; CIPROFLOXACIN; CONDITIONED MEDIUM; MOXIFLOXACIN; PEPTIDE HYDROLASE; QUINOLONE DERIVATIVE; STREPTOMYCIN;

CHEMISTRY; CONDITIONED MEDIUM; DNA SEQUENCE; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENETICS; HEAT; HUMAN; LACTOBACILLUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PH; PHARMACOLOGY; PHYSICAL CHEMISTRY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; URINARY TRACT INFECTIONS; VAGINA;

ANTI-BACTERIAL AGENTS; CIPROFLOXACIN; CULTURE MEDIA, CONDITIONED; DNA, BACTERIAL; DRUG SYNERGISM; FEMALE; FLUOROQUINOLONES; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOBACILLUS; MICROBIAL SENSITIVITY TESTS; PEPTIDE HYDROLASES; PHYSICOCHEMICAL PHENOMENA; PSEUDOMONAS AERUGINOSA; SEQUENCE ANALYSIS, DNA; STREPTOMYCIN; URINARY TRACT INFECTIONS; VAGINA;

EID: 84940007235     PISSN: 18671306     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12602-015-9188-4     Document Type: Article

References (35)

1. National Nosocomial Infections Surveillance system report (1999) Data summary from January 1990–May 1999. Am J Infect Control 2:520–532
2. Goossens H (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 9:980–983
3. Poole K (2004) Efflux-mediated multi resistance in Gram-negative bacteria. Clin Microbiol Infect 10:12–26
4. National Nosocomial Infections Surveillance system report (2004) Data summary from January 1992 through June 2004. Am J Infect Control 32:470–485
5. Pépin J, Saheb N, Coulombe M, Alary M, Corriveau M, Authier S et al (2005) Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile–associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260
6. Morita Y, Tomida J, Kawamura Y (2014) Responses of Pseudomonas aeruginosa to antimicrobials. Front Microbiol. doi:10.3389/fmicb.2013.00422
7. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, de Champs C (2008) Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in ICU-patients. Crit Care 12:R69. doi:10.1186/cc6907
8. Stapleton AE, Au-Yeung M, Hooton TM, Fredericks DN, Roberts PL, Czaja CA et al (2011) Randomized, placebo-controlled phase 2 clinical trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 52:1212–1217
9. Pavlova SI, Kilic AO, Kilic SS, So JS, Nader-Macias ME, Simoes JA et al (2002) Genetic diversity of vaginal lactobacilli from women in different countries based on 16S rRNA gene sequences. J Appl Microbiol 92:451–459
10. Lakshminarayanan B, Guinane CM, O’Connor PM, Coakley M, Hill C, Stanton C et al (2013) Isolation and characterization of bacteriocin-producing bacteria from the intestinal microbiota of elderly Irish subjects. J Appl Microbiol 114:886–898
11. Kim J, Rajagopal SN (2001) Antibacterial activities of Lactobacillus crispatus ATCC 33820 and Lactobacillus gasseri ATCC 33323. J Microbiol 39:146–148
12. Tahara T, Kanatani K (1997) Isolation and partial characterisation of crispacin, a cell-associated bacteriocin produced by Lactobacillus crispatus JCM 2009. FEMS Microbiol Lett 147:287–290
13. de Man JC, Rogosa M, Sharpe ME (1960) A medium for the cultivation of lactobacilli. J Appl Bacteriol 23:130–135
14. Holt JG, Krieg NR, Sneath PH, Staley JT, Williams ST (1994) Bergeys manual of determinative bacteriology, 9th edn. Lippincott Williams and Wilkins, Baltimore
15. Moore E, Arnscheidt A, Kuger A, Strompl C, Mau M (2004) Simplified protocols for the preparation of genomic DNA from bacterial cultures. In: Kowalchuk GA, de Bruijn FJ, Head IM, Van der Zijpp AJ, van Elsas JD (eds) Molecular microbial ecology manual, 2nd edn. Kluwer Academic Publishers, Netherland, pp 3–18
16. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215:403–410
17. Geis A, Singh J, Teuber M (1983) Potential of lactic streptococci to produce bacteriocin. Appl Environ Microbiol 45:205–211
18. Melancon D, Grenier D (2003) Production and properties of bacteriocin-like inhibitory substances from the swine pathogens Streptococcus suis serotype 2. Appl Environ Microbiol 69:4482–4488
19. Bauer AW, Kirby MM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol 45:493–496
20. National Committee for clinical laboratory standards (2000) Performance standards for antimicrobial disk susceptibility tests, 7th edn. Approved standard M2-A7. NCCLS, Wayne
21. Ruíz FO, Gerbaldo G, García MJ, Giordano W, Pascual L, Barberis IL (2012) Synergistic effect between two bacteriocin-like inhibitory substances produced by lactobacilli strains with inhibitory activity for Streptococcus agalactiae. Curr Microbiol 64:349–356
22. Petersen P, Labthavikul P, Jones C, Bradford P (2006) In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 57:573–576
23. Dicks LMT, Heunis TDJ, Staden DAV, Brand A, Noll KS, Chikindas ML (2011) Medical and personal care applications of bacteriocins produced by Lactic acid bacteria. In: Drider D, Rebuffat S (eds) Prokaryotic antimicrobial peptides: from genes to applications. Springer, New York, pp 391–421
24. Cotter PD, Ross RP, Hill C (2013) Bacteriocins—a viable alternative to antibiotics? Nat Rev Microbiol 11:95–105
25. Dobson A, Cotter R, Ross P, Hill C (2012) Bacteriocin production: a probiotic trait? Appl Environ Microbiol 78:1–6. doi:10.1128/AEM.05576-11
26. Al-Mathkhury HJF, Ali AS, Ghafil JA (2011) Antagonistic effect of bacteriocin against urinary catheter associated Pseudomonas aeruginosa biofilm. N Am J Med Sci 3(8):367–370. doi:10.4297/najms.2011.3367
27. Majhenic AC, Matijasic BB, Rogelj I (2003) Chromosomal location of the genetic determinants for bacteriocins produced by Lactobacillus gasseri K7. J Dairy Res 70:199–203. doi:10.1017/S0022029903006162
28. Stover CK, Pham XQ, Erwin AL et al (2000) Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 406:959–964
29. Gálvez A, Abriouel H, López RL, Omar NB (2007) Bacteriocin-based strategies for food biopreservation. Int J Food Microbiol 120:51–70
30. Rishi P, Preet S, Kaur P (2011) Effect of L. plantarum cell-free extract and co-trimoxazole against Salmonella typhimurium: a possible adjunct therapy. Ann Clin Microbiol Antimicrob 10:9. doi:10.1186/1476-0711-10-9
31. Giacometti A, Cirioni O, Barcheisi M, Fortuna M, Scarleise E (1999) In vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. J Antimicrob Chemother 44:641–645
32. Mataraci E, Dosler S (2012) In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother 56:6366–6371
33. Draper LA, Cotter PD, Hill C, Ross RP (2013) The two peptide lantibiotic lacticin 3147 acts synergistically with polymyxin to inhibit Gram negative bacteria. BMC Microbiol 13:212. doi:10.1186/1471-2180-13-212
34. Drlica K, Zhao XK (1997) DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 61:377–392
35. Hancock RE (1997) Peptide antibiotics. Lancet 349:418–422